Higher dose hormone therapy aims to control rare calcium disorder
NCT ID NCT07081997
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This phase 3 trial tests higher daily doses (over 30 mcg) of palopegteriparatide (Yorvipath) in 36 adults with chronic hypoparathyroidism. Participants already on the drug will have their dose adjusted to find the best level for controlling calcium without needing extra vitamin D or calcium supplements. The study lasts 78 weeks and focuses on safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPARATHYROIDISM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ascendis Pharma Investigational Site
RECRUITINGReno, Nevada, 89511, United States
-
Ascendis Pharma Investigational Site
RECRUITINGNew York, New York, 10032, United States
-
Ascendis Pharma Investigational Site
RECRUITINGSpokane Valley, Washington, 99216, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
palopegteriparatide (Yorvipath)
What this could lead to
If successful, this could provide a more effective way to manage hypoparathyroidism with higher doses, reducing the need for calcium and vitamin D supplements.
What could go wrong
This is a small, open-label trial with only 36 participants, so results may not apply broadly. Higher doses may also increase side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.